Skip to main content

Nasdaq Warns BG Medicine Again on Listing Requirement

NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet another requirement to remain listing on the Nasdaq Global Market, the company said in a document filed with the US Securities and Exchange Commission on Wednesday.

In a Nov. 22 letter from Nasdaq, BG Medicine was told that its publicly held shares closed below the minimum $15 million threshold for the preceding 30 consecutive business days, putting the company at risk of being delisted. BG Medicine has until May 21, 2014 to regain compliance.

The firm also is in danger of being listed from Nasdaq for failing to meet two other requirements. Earlier this month the exchange notified the company that it has not regained compliance with a listing requirement of at least $50 million in market value of its listed securities. BG Medicine has requested a hearing with a Nasdaq panel on the matter.

Additionally, BG Medicine is not in compliance with a listing requirement calling for a minimum $1 closing bid price on its stock. It has until March 24, 2014 to regain compliance with that rule.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.